Psoriasis is a common chronic inflammatory skin disease characterized by recurrent erythematous plaques, involving abnormal proliferation of keratinocytes and immune dysregulation, which significantly ...

Innovent has posted another psoriasis win for its IL-23 contender to the likes of Tremfya and Skyrizi while the company awaits an approval decision by Chinese regulators. The anti-IL-23 monoclonal ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the biotech’s hopes it can provide a new oral option for patients with psoriasis.

Please provide your email address to receive an email when new articles are posted on . Although multiple therapies, including systemic and biologic treatments, are effective in treating psoriasis, ...

A recent survey from the GW School of Medicine and Health Sciences found patients with psoriasis frequently use complementary or alternative therapies to treat their symptoms when traditional ...

For adults and adolescents with moderate-to-severe plaque psoriasis, selective blockade of the interleukin-23 receptor with the targeted oral peptide icotrokinra yields a significantly higher ...